Millennium Management
ENTA icon

Millennium Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Millennium Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-190,400
Closed -$2.28M – 6110
2025
Q3 		$2.28M Buy
190,400
+140,400
+281% +$1.12M ﹤0.01% 3931
2025
Q2 		$378K Buy
+50,000
New +$301K ﹤0.01% 5072

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management's ENTA Position: Q1 2026 in Review

Millennium Management increased its Enanta Pharmaceuticals (ENTA) stake by 32% in Q1 2026, buying an estimated $2.84M and bringing the position to 882,097 shares worth $11.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2069.

Millennium Management first reported a position in ENTA in Q4 2013 and has held it in 43 quarters since. The position peaked at $17.5M in Q2 2017. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Millennium Management held 882,097 shares of Enanta Pharmaceuticals worth $11.1M as of Q1 2026.
  • Millennium Management bought 211,669 Enanta Pharmaceuticals shares in Q1 2026, an estimated $2.84M.
  • Enanta Pharmaceuticals made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2069 holding.
  • Millennium Management first reported a position in Enanta Pharmaceuticals in Q4 2013 and has held it in 43 quarters since.
  • Millennium Management's Enanta Pharmaceuticals position peaked at $17.5M in Q2 2017.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.